Key Points
- Thermo Fisher EVP Frederick Lowery sold 6,912 shares at an average price of $581.94 on Dec. 2, totaling $4,022,369.28 and reducing his stake by 32.48% to 14,367 shares (≈$8.36M).
- The company beat Q results with EPS $5.79 (vs. $5.50) and revenue $11.12B, set FY2025 guidance of 22.600–22.860 EPS, declared a quarterly dividend of $0.43 (0.3% yield), and authorized a $5B share buyback.
Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) EVP Frederick Lowery sold 6,912 shares of the company's stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $581.94, for a total transaction of $4,022,369.28. Following the completion of the sale, the executive vice president directly owned 14,367 shares of the company's stock, valued at $8,360,731.98. The trade was a 32.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Thermo Fisher Scientific Stock Performance
Shares of TMO stock opened at $580.61 on Thursday. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $610.97. The stock's 50-day moving average price is $555.23 and its 200 day moving average price is $483.27. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $218.14 billion, a PE ratio of 33.54, a price-to-earnings-growth ratio of 4.28 and a beta of 0.90.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. During the same quarter in the previous year, the company posted $5.28 earnings per share. The company's revenue for the quarter was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.
Thermo Fisher Scientific Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific's payout ratio is currently 9.94%.
Thermo Fisher Scientific declared that its board has initiated a stock buyback program on Thursday, November 6th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical research company to reacquire up to 2.4% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's management believes its stock is undervalued.
Institutional Trading of Thermo Fisher Scientific
Several hedge funds and other institutional investors have recently modified their holdings of TMO. Mondrian Investment Partners LTD boosted its stake in shares of Thermo Fisher Scientific by 146.1% during the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company's stock worth $106,738,000 after acquiring an additional 127,357 shares in the last quarter. TIAA Trust National Association boosted its position in shares of Thermo Fisher Scientific by 10.5% in the second quarter. TIAA Trust National Association now owns 123,948 shares of the medical research company's stock valued at $50,256,000 after acquiring an additional 11,817 shares during the period. Caledonia Investments PLC grew its position in Thermo Fisher Scientific by 11.5% in the 2nd quarter. Caledonia Investments PLC now owns 111,767 shares of the medical research company's stock worth $45,299,000 after purchasing an additional 11,500 shares during the last quarter. Heritage Investors Management Corp raised its holdings in Thermo Fisher Scientific by 9.6% in the 2nd quarter. Heritage Investors Management Corp now owns 56,587 shares of the medical research company's stock valued at $22,944,000 after acquiring an additional 4,971 shares in the last quarter. Finally, LBP AM SA boosted its stake in Thermo Fisher Scientific by 13.4% during the second quarter. LBP AM SA now owns 261,038 shares of the medical research company's stock worth $105,840,000 after buying an additional 30,837 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities research analysts have commented on the stock. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday, October 25th. Royal Bank Of Canada set a $561.00 price objective on Thermo Fisher Scientific and gave the stock an "outperform" rating in a report on Tuesday, September 2nd. Morgan Stanley lifted their price target on shares of Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an "overweight" rating in a report on Tuesday. Barclays increased their price target on Thermo Fisher Scientific from $585.00 to $625.00 and gave the company an "overweight" rating in a report on Thursday, October 23rd. Finally, Redburn Partners set a $580.00 target price on shares of Thermo Fisher Scientific in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $602.35.
View Our Latest Analysis on TMO
Thermo Fisher Scientific Company Profile
(
Get Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
